The new ICP DAS Biomedical Division was officially established in June 2018, and a press conference on the completion of the Biomedical Polymer Factory was held on November 4, 2019.
As the main goal of the first phase of the plant, General Manager Robert Chen said that, following the completion and opening of the biomedical polymer factory, the focus in the future would be long-term investment in research and development, together with the production of medical thermoplastic polyurethane (TPU) that had a stable and reliable quality.
The ICP DAS Biomedical Polymer Factory is a production plant planned in accordance with the ISO13485 standard. The initial plan is to manufacture medical TPU as the main goal. As expected, the pilot production has been running since the first quarter of 2020, and is expected that certification for the ISO13485 quality system for medical TPU materials will be completed by the fourth quarter of 2020.
The plant covers an area of about 11,000 square meters. The production plant consists of raw material warehouses, TPU production lines, quality control facilities, and finished goods warehouses. In addition to the production site, this factory also includes R&D laboratories for TPU polymerization and processing, as well as physical and chemical analysis. In order to support the safety assessment for the medical TPU material, a fully-equipped cell culture laboratory has also been established at the plant.
Related News:
Leave a Reply